Gilead Sciences Inc has priced its COVID-19 drug candidate remdesivir at $2,340 for a five-day treatment in the United States and some other developed countries, potentially reflecting looming competition from…

Read more »

The post Gilead Prices COVID-19 Drug Candidate Remdesivir at $2,340/Patient appeared first on Hamodia.

In related news:

  1. Gilead’s Remdesivir Meets Main Goal of Trial in COVID-19 Patients
  2. Swedish Agency Says EU ‘Studying’ Remdesivir
  3. ‘Glimmer of Hope’ Seen for Remdesivir Trials
  4. Gilead Disputes Report That Its Drug Flopped in Coronavirus Trial
  5. Remdesivir Donation Approved by Cabinet